Tuesday, 08 October 2024 03:40 AM
Company Update
PHILADELPHIA, PA / ACCESSWIRE / October 8, 2024 / Thrive Genetics is excited to announce the launch of its flagship product, the Thrive CARE (Comprehensive Addiction Risk Evaluation) System. This milestone is the result of several years of dedicated development and highlights the company's commitment to advancing personalized, data-driven strategies for managing addiction risks and improving overall health outcomes.
Founded in March 2023, Thrive Genetics has quickly established a robust foundation with a diverse array of customers, including partnerships with veterans' organizations and various hospitals. The company was born from a mission to empower individuals and organizations through personalized insights driven by advanced genomics and data analytics.
"We're excited to unveil a comprehensive digital health platform that combines cutting-edge technology with a deep understanding of our customers' needs. Our approach ensures that as we launch, we're delivering a product that resonates with those we aim to serve," says CEO James Piacentino
With over ten years of research and over $50M of grant research funds behind it, the Thrive CARE System provides users with actionable, science-backed strategies for identifying personalized addiction risk. It operates through a user-friendly interface that allows individuals to uncover their genetic predisposition to addiction by simply completing a survey and providing a saliva sample for genetic analysis. The platform integrates behavioral and environmental factors alongside genetic information to create a comprehensive risk profile unique to each user. This dual approach not only enhances the accuracy of risk assessments but also empowers individuals to make informed decisions about their health and well-being.
Thrive Genetics is focused on several key customer segments, including healthcare providers who require proactive, data-driven recommendations to enhance patient experiences and outcomes. The company sees significant opportunities within corporate wellness programs, where billions are spent annually on addiction-related services as part of employee health and wellness initiatives, and will consider a DTC option for buyers at a later stage.
In addition, the company is committed to supporting the US Veteran population in developing long-term treatment options that effectively address possible mental health and PTSD-related addiction challenges. By partnering with addiction treatment centers and clinics, Thrive Genetics aims to streamline personalized care and achieve outcome-based cost savings in outpatient treatment processes.
At the core of Thrive Genetics' mission is the pressing problem of addiction that costs the US healthcare system hundreds of billions of dollars each year and affects millions of individuals. Traditional approaches often fall short in identifying those at risk and providing actionable solutions. This focus positions the company to make a meaningful impact in the lives of individuals at risk of addiction while also providing healthcare providers and organizations with the tools they need to deliver better outcomes for their patients.
The evolution of Thrive Genetics' mission is centered on providing science-backed, personalized insights for addiction risk management. Looking to the future, Piacentino shared, "As we look ahead, we are dedicated to proving our value in specific markets while expanding into new domains. Our long-term goal is to create a seamless integration of personalized insights across various customer verticals, ultimately transforming addiction management on a global scale."
For more information about Thrive Genetics, visit thrivegenetics.ai.
Company: Thrive Genetics
Address: 30S 15th Street, Philadelphia, PA 19102
Email:[email protected]
Website: thrivegenetics.ai
SOURCE: Thrive Genetics